This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Flamel Undisclosed UMD #4

Flamel Technologies

Drug Names(s): Éclat Drug #4

Description: This compound was originally developed by Éclat Pharmaceuticals.

Flamel stated that it plans to file an NDA for a fourth undisclosed compound. BioMedTracker will update this profile when further information becomes available.

Deal Structure: Flamel and clat
In March 2012, Flamel Technologies acquired clat Pharmaceuticals.

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug